Notebook

HERE WE GO AGAIN: More breast cancer genes are likely, says Duke's Futreal. A recent report in Nature Genetics (C. Phelan et al., 13:120-2, 1996) suggests that mutations in BRCA2, the second breast cancer susceptibility gene identified, may not be involved in as many cases of inherited breast cancer as first thought, but it may play a role in some pancreatic cancers. At the same time, the work implies that a third breast cancer gene-and perhaps more-may lurk in human DNA. Researchers at Duke

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

HERE WE GO AGAIN: More breast cancer genes are likely, says Duke's Futreal. A recent report in Nature Genetics (C. Phelan et al., 13:120-2, 1996) suggests that mutations in BRCA2, the second breast cancer susceptibility gene identified, may not be involved in as many cases of inherited breast cancer as first thought, but it may play a role in some pancreatic cancers. At the same time, the work implies that a third breast cancer gene-and perhaps more-may lurk in human DNA. Researchers at Duke University Medical Center and the National Institute of Environmental Health Sciences in Research Triangle Park, N.C., studied 49 families with inherited breast cancers unlikely to have mutations in the BRCA1 gene, the initial breast cancer susceptibility gene uncovered in 1994. Together, BRCA1 and BRCA2 are thought to be responsible for about 90 percent of the 5 percent to 10 percent of breast cancers that run in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies